MedTrace Logo

Adjuvant Avelumab in Merkel Cell Cancer

NCT03271372 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 101

Last updated 2026-05-12

No results posted yet for this study

Summary

This randomized phase III trial studies how well avelumab works in treating patients with Merkel cell cancer that has spread to the lymph nodes and have undergone surgery and/or radiation therapy. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Conditions

  • Stage III Merkel Cell Carcinoma AJCC v8
  • Stage IIIB Merkel Cell Carcinoma AJCC v8
  • Stage IIIA Merkel Cell Carcinoma AJCC v8

Interventions

DRUG

Avelumab

Given IV

OTHER

Peripheral Blood Collection

Correlative studies

OTHER

Placebo

Given IV

Sponsors & Collaborators

Principal Investigators

  • Shailender Bhatia · Fred Hutch/University of Washington Cancer Consortium

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-19
Primary Completion
2026-04-03
Completion
2029-02-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03271372 on ClinicalTrials.gov